Osteonecrosis of the jaw related to sunitinib

被引：89

作者：

Koch F.P. ^{[1
]}

Walter C. ^{[1
]}

Hansen T. ^{[2
]}

Jäger E. ^{[3
]}

Wagner W. ^{[1
]}

机构：

[1] Oral and Maxillofacial Surgery, University Medical Centre of the Johannes Gutenberg University, 55131 Mainz, Mund-, Kiefer-und Gesichtschirurgie

[2] Institute of Pathology, University Medical Centre of the Johannes Gutenberg University, Mainz

[3] Clinic for Oncology and Haematology, Krankenhaus Nordwest, Frankfurt a.M.

来源：

Oral and Maxillofacial Surgery | 2011年 / 15卷 / 1期

关键词：

Cancer therapy; Multi-kinase inhibitor; Osteonecrosis; Side effect; Sunitinib; Tooth extraction;

D O I：

10.1007/s10006-010-0224-y

中图分类号：

学科分类号：

摘要：

Case Report: A 59-year-old male patient was referred to the hospital with exposed bone measuring 10 mm in diameter in the posterior, left-side region of the lower jaw. Two months previous, the first molar had been extracted. The patient had contracted renal cell carcinoma and had been treated by nephrectomy in 2003. Soft tissue metastases occurred. After initial therapy with interferon and vinblastine, a relapse occurred and the therapy was changed to sorafenib, followed by sunitinib. Osteonecrosis of the lower jaw appeared 1 year after initial and exclusive therapy with sunitinib. Conclusions: Bisphosphonates had never been applied. With increasing application of multi-kinase inhibitors, complications due to osteonecrosis could occur more frequently. © 2010 Springer-Verlag.

引用

页码：63 / 66

页数：3

共 26 条

[1]

Chow L.Q., Eckhardt S.G., Sunitinib: from rational design to clinical efficacy, J Clin Oncol, 25, pp. 884-896, (2007)

[2]

Haas N.B., Uzzo R.G., Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer, Curr Treat Options in Oncol, 8, pp. 211-226, (2007)

[3]

Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J.M., In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relati

[4]

Arora A., Scholar E.M., Role of tyrosine kinase inhibitors in cancer therapy, J Pharmacol Exp Ther, 315, pp. 971-979, (2005)

[5]

Sundberg C., Ljungstrom M., Lindmark G., Gerdin B., Rubin C., Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma, Am J Pathol, 143, pp. 1377-1388, (1993)

[6]

Ayllon J., Launay-Vacher V., Medioni J., Cros C., Spano J.P., Oudard S., Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?, Ann Oncol, 20, pp. 600-601, (2009)

[7]

Brunello A., Saia G., Bedogni A., Scaglione D., Basso U., Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma, Bone, 44, pp. 173-175, (2009)

[8]

Christodoulou C., Pervena A., Klouvas G., Galani E., Falagas M.E., Tsakalos G., Visvikis A., Nikolakopoulou A., Acholos V., Karapanagiotidis G., Batziou E., Skarlos D.V., Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone, Oncology, 76, pp. 209-211, (2009)

[9]

Assael L.A., New foundations in understanding osteonecrosis of the jaws, J Oral Maxillofac Surg, 62, pp. 125-126, (2004)

[10]

Chrcanovic B.R., Reher P., Sousa A.A., Harris M., Osteoradionecrosis of the jaws-a current overview-part 1: physiopathology and risk and predisposing factors, Oral Maxillofac Surg, 14, pp. 3-16, (2010)

← 1 2 3 →